Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 12/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 12/20 | 0.36 |
| ▸ | CHRNB3 | Q05901 | 4/20 | 0.36 |
| ▸ | CHRNA6 | Q15825 | 4/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 8/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29985317 | 0.75 | — | — | |
| SCHEMBL25921394 | 0.73 | CHRNB2 (0.39) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL29985475 | 0.73 | CHRNB2 (0.39) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL25910352 | 0.70 | CHRNB2 (0.33) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL25911012 | 0.68 | CHRNB2 (0.38) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL25910504 | 0.68 | HRH3 (0.35) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL25911019 | 0.68 | CHRNB2 (0.35) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL25910517 | 0.67 | CHRNB2 (0.33) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL29299288 | 0.64 | HRH3 (0.32) | — | |
| SCHEMBL25910088 | 0.64 | EPHX2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252497-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240277796-A1 | METHODS FOR INHIBITING RAS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-08-22 | — | — | US | disclosed |
| EP-4346898-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4334325-A1 | RAS INHIBITORS FOR THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20220396589-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2022-12-15 | — | — | US | disclosed |
| WO-2022251292-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022235870-A1 | RAS INHIBITORS FOR THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396589-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CHRNB2 4867/4885CHRNA3 4866/4885CHRNA4 4880/4885 |
| US-12252497-B2 | Ras inhibitors | KRAS, NRAS, HRAS | CHRNB2 4867/4885CHRNA3 4866/4885CHRNA4 4880/4885 |
| US-20240277796-A1 | METHODS FOR INHIBITING RAS | KRAS, HRAS, NRAS | CHRNB2 4174/4885CHRNA3 4433/4885CHRNA4 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.